Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

21-23 April 2017

Prague, Czech Republic

Scientific Agenda

Friday, 21 April 2017

14:00

Welcome and introduction
Srdan Verstovsek, MD, PhD and Alessandro M. Vannucchi, MD

Session I: Biology of Myeloproliferative Neoplasms and Myelodysplastic Syndromes

Moderator: Radek C. Skoda, MD

14:05

Pre-session audience survey

14:15

Genetic basis of MDS
Luca Malcovati, MD

14:35

Advances in understanding of MDS microenvironment
Carmen Aanei, MD, PhD

14:55

Role of immune system in MDS pathogenesis
Astrid Olsnes Kittang, MD

15:15

Break and poster viewing

15:45

New mouse models of MPN
Radek C. Skoda, MD

16:05

Mechanisms of bone marrow fibrosis in Myelofibrosis
Jean Luc Villeval, PhD

16:25

Post-session audience survey

16:30

Panel discussion and questions

16:45

Take-home points

16:50

Adjourn
 

Saturday, 22 April 2017

9:30

Welcome to day 2
Srdan Verstovsek, MD, PhD and Alessandro M. Vannucchi, MD

Session II: Clinical Aspects of Myeloproliferative Neoplasms (I)

Moderator: Martin Griesshammer, MD

9:35

Pre-session audience survey

9:45

Biology and therapy of eosinophilic neoplasms
Andreas Reiter, MD

10:05

Topical challenges in the management of ET
Jiří Schwarz, MD, PhD

10:25

Diagnostic and treatment enigmas in PV
Carlos Besses, MD, PhD

10:45

Break and poster viewing

11:15

What is new in thrombosis in MPN
Tiziano Barbui, MD

11:35

My view on current and future use of JAK inhibitors for ET, PV, and MF
Martin Griesshammer, MD

11:55

Post-session audience survey

12:00

Panel discussion and questions

12:15

Lunch

Session III: Clinical Aspects of Myelodysplastic Syndromes

Moderator: Eva Hellström-Lindberg, MD, PhD

14:15

Pre-session audience survey

14:25

Hypocellular MDS vs. aplastic anemia - Diagnosis and therapy
Austin G. Kulasekararaj, MD, MRCP, FRCPath

14:45

My approach to MDS management
Eva Hellström-Lindberg, MD, PhD

15:05

Break and poster viewing

15:35

Iron chelation therapy for MDS
Norbert Gattermann, MD, PhD

15:55

Optimal use of lenalidomide as therapy for MDS
Aristoteles Giagounidis, MD

16:15

Experimental therapeutics in MDS – New opportunities
Jaroslav Cermak, MD, PhD

16:35

Post-session audience survey

16:40

Panel discussion and questions

16:55

Adjourn
 

Sunday, 23 April 2017

9:00

Welcome to day 3
Srdan Verstovsek, MD, PhD and Alessandro M. Vannucchi, MD

Session IV: Clinical Aspects of Myeloproliferative Neoplasms (II)

Moderator: Claire Harrison, DM, FRCP, FRCPath

9:05

Pre-session audience survey

9:15

MF marrow morphology: Key takeaways from WHO 2016 diagnostic update
Hans Michael Kvasnicka, MD, PhD

9:35

MF as inflammatory disease
Steffen Koschmieder, MD, PhD

9:55

My approach to MF management
Claire Harrison, DM, FRCP, FRCPath

10:15

Break and poster viewing

10:45

Clonal evolution of MPN to accelerated or blastic phase: Therapeutic insights
Srdan Verstovsek, MD, PhD

11:05

Experimental therapeutics in MPN: where is the field going
Alessandro M. Vannucchi, MD

11:25

Post-audience survey

11:30

Panel discussion and questions

11:45

Adjourn